LucchinettiCFGavrilovaRHMetzI. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain2008; 131: 1759–1775.
2.
HardyTAChatawayJ. Tumefactive demyelination: An approach to diagnosis and management. J Neurol Neurosurg Psychiatry2013; 84: 1047–1053.
3.
GivenCAStevensBSLeeC. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol2004; 182: 195–199.
4.
MalhotraHSJainKKAgarwalA. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler2009; 15:193–203.
5.
SilvaHCCallegaroDMarchioriPE. Magnetic resonance imaging in five patients with a tumefactive demyelinating lesion in the central nervous system. Arq Neuropsiquiatr1999; 57: 921–926.
6.
ZagzagDMillerDCKleinmanGM. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol1993; 17: 537–545.
7.
SiffrinVMüller-ForellWvon PeinH. How to treat tumefactive demyelinating disease?Mult Scler J2013. [Epub ahead of print: DOI: 10.1177/1352458513516891].
8.
AltintasAPetekBIsikN. Clinical and radiological characteristics of tumefactive demyelinating lesions: Follow-up study. Mult Scler2012; 18: 1448–1453.
9.
HouraniRBrantLJRizkT. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults?AJNR Am J Neuroradiol2008; 29: 366–372.
10.
LawMMeltzerDEChaS. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology2002; 44: 986–989.
11.
CianfoniANikuSImbesiSG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol2007; 28: 272–277.
12.
MajósCAguileraCAlonsoJ. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol2009; 30: 544–551.
